UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

Non-viral precision T cell receptor replacement for personalized cell therapy

Nature (London), 2023-03, Vol.615 (7953), p.687-696

2023

Link zum Volltext

Verfügbarkeit prüfen

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.231-247

2020

Link zum Volltext

Verfügbarkeit prüfen

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer

Clinical cancer research, 2020-07, Vol.26 (13), p.3287-3295

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature communications, 2023-07, Vol.14 (1), p.4238-4238, Article 4238

2023

Link zum Volltext

Verfügbarkeit prüfen

Acquired Resistance to Immune Checkpoint Inhibitors

Cancer cell, 2020-04, Vol.37 (4), p.443-455

2020

Link zum Volltext

Verfügbarkeit prüfen

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.802-815

2019

Link zum Volltext

Verfügbarkeit prüfen

Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer

Clinical cancer research, 2022-09, Vol.28 (17), p.3797-3803

2022

Link zum Volltext

Verfügbarkeit prüfen

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Nature communications, 2021-06, Vol.12 (1), p.3697-3697, Article 3697

2021

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Nature communications, 2022-09, Vol.13 (1), p.5579-5579, Article 5579

2022

Link zum Volltext

Verfügbarkeit prüfen

The Evolving Landscape of Resistance to Osimertinib

Journal of thoracic oncology, 2020-01, Vol.15 (1), p.18-21

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2654-2663

2020

Link zum Volltext

Verfügbarkeit prüfen

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (11), p.e007618

2023

Link zum Volltext

Verfügbarkeit prüfen

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Clinical cancer research, 2020-11, Vol.26 (21), p.5701-5708

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for immunotherapy of cancer, 2023-07, Vol.11 (7), p.e006994

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer

Future oncology (London, England), 2024-04, Vol.20 (13), p.851-862

2024

Link zum Volltext

Verfügbarkeit prüfen

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Clinical cancer research, 2021-05, Vol.27 (10), p.2920-2927

2021

Link zum Volltext

Verfügbarkeit prüfen

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Clinical cancer research, 2021-05, Vol.27 (10), p.2899-2909

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.258-265

2020

Link zum Volltext

Verfügbarkeit prüfen

Letter to the Editor: Reply to Zhao, Wu, and Ma

Journal of thoracic oncology, 2023-06, Vol.18 (6), p.e61-e62

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.463-475

2023

Link zum Volltext

Verfügbarkeit prüfen

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

Clinical cancer research, 2020-06, Vol.26 (12), p.2932-2945

2020

Link zum Volltext

Verfügbarkeit prüfen

How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?

The cancer journal (Sudbury, Mass.), 2021-03, Vol.27 (2), p.134

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(99)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(54)
Humans
(53)
Oncology
(36)
Lung Neoplasms - Genetics
(24)
Female
(18)
Carcinoma, Non-Small-Cell Lung - Genetics
(17)
Lung Neoplasms - Drug Therapy
(17)
Male
(17)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(15)
Middle Aged
(14)
Aged
(13)
Immunotherapy
(13)
Retrospective Studies
(13)
Adult
(11)
Mutation
(11)
Carcinoma, Non-Small-Cell Lung - Pathology
(10)
Lung Cancer
(10)
Lung Neoplasms - Pathology
(10)
Respiratory System
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Non-viral precision T cell receptor replacement for personalized cell therapy

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Acquired Resistance to Immune Checkpoint Inhibitors

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers

Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

The Evolving Landscape of Resistance to Osimertinib

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Letter to the Editor: Reply to Zhao, Wu, and Ma

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial

Suchergebnisse filtern